21世紀における心不全への対策
1Johns Hopkins Medical Institutions, 720 Rutland Avenue, Ross 835, Baltimore, Maryland 21205, USA.
Nature
|February 22, 2008
まとめ
心不全は,心臓が十分な量の血をポンプにできない深刻な状態です. 進歩にもかかわらず,特に高齢者層では依然として主要な死因であり,新しい治療法が必要である.
科学分野:
- 心臓病学 心臓病学
- 分子生物学は分子生物学である.
- ゲロントロジーはゲロントロジーの学科です.
背景:
- 心不全 (HF) または充血性心不全は,心臓が十分な血流を提供する能力を低下させます.
- これは,疲労や呼吸困難などの重度の症状を引き起こし,しばしば死亡につながる.
- 慢性HFは,罹病率と死亡率の重要な原因であり,高齢者集団で増加している.
研究 の 目的:
- 心不全の理解における進展をレビューする.
- 新しい治療戦略の必要性を強調する.
- 高齢化人口における心不全の増大する負担に対処するために.
主な方法:
- 心不全における分子および細胞プロセスのレビュー.
- 現在の治療の進歩の分析.
- 心不全における疫学的傾向の検討.
主要な成果:
- 心不全のメカニズムを理解するうえで,著しい進展がみられた.
- 効果的な治療法が開発されていますが,慢性高血圧症は主要な健康問題として依然として存在しています.
- 世界の人口の高齢化により,心不全の発生率は増加しています.
結論:
- 治療の進歩にもかかわらず,慢性心不全は依然として重大な健康上の課題です.
- 細胞および臓器レベルのメカニズムを標的とした新しい治療法は不可欠です.
- 心不全の治療は,高齢者における心不全の増加傾向を考慮すると極めて重要です.
関連する概念動画
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...